Apriem Advisors’s Capricor Therapeutics CAPR Stock Holding History

Apriem Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,000	Closed	-$23K	–	132
2019 Q1	$23K	Hold	5,000	–	–	0.01%	126
2018 Q4	$21K	Hold	5,000	–	–	0.01%	125
2018 Q3	$53K	Hold	5,000	–	–	0.01%	144
2018 Q2	$67K	Hold	5,000	–	–	0.02%	215
2018 Q1	$68K	Hold	5,000	–	–	0.02%	129
2017 Q4	$79K	Hold	5,000	–	–	0.02%	128
2017 Q3	$152K	Hold	5,000	–	–	0.04%	133
2017 Q2	$42K	Hold	5,000	–	–	0.01%	135
2017 Q1	$169K	Buy	+5,000	New	+$139K	0.05%	136
2016 Q4	–	Sell	-7,096	Closed	-$230K	–	713
2016 Q3	$230K	Hold	7,096	–	–	0.07%	107
2016 Q2	$280K	Hold	7,096	–	–	0.09%	90
2016 Q1	$180K	Buy	+7,096	New	+$172K	0.07%	100

Other funds holding CAPR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CFN

Cordasco Financial Network Naples, Florida $138M AUM 10.5% 1-Year Est. Return

Apriem Advisors's CAPR Position: Q2 2019 in Review

Apriem Advisors sold out of Capricor Therapeutics (CAPR) in Q2 2019, closing a stake of 5,000 shares — an estimated $23K sold.

Apriem Advisors first reported a position in CAPR in Q1 2016 and held it in 12 quarters. The position peaked at $280K in Q2 2016. 12 funds tracked by Wall St. Rank hold CAPR as of Q2 2019.

Apriem Advisors reported no remaining Capricor Therapeutics position as of Q2 2019 after selling out during the quarter.
Apriem Advisors sold 5,000 Capricor Therapeutics shares in Q2 2019, an estimated $23K.
Apriem Advisors first reported a position in Capricor Therapeutics in Q1 2016 and held it in 12 quarters.
Apriem Advisors's Capricor Therapeutics position peaked at $280K in Q2 2016.
12 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2019.

Based on Apriem Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.